SCHEMBL3955904

SCHEMBL3955904

CCOC(=O)c1cc2c(N)n[nH]c2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
CSNK2A2 P19784 1/20 0.43
KDR P35968 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
MAPK10 P53779 1/20 0.42
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HPGD P15428 4/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14163467 0.87 PDE4D (0.47) KDM4ECSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL763925 0.87 TSHR (0.43) KDM4ESMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL27243884 0.84 KDM4E (0.43) KDM4ECSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL12895640 0.84 CSNK2A2 (0.56) KDM4ECSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL742663 0.81 CSNK2A2 (0.40) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL3891670 0.79 KDM4E (0.42) KDM4ESMN1; SMN2HTTMAPK10ALDH1A1
SCHEMBL3835960 0.77 MAP3K8 (0.39) KDM4ECSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL347014 0.75 MAPK14 (0.44) KDM4EKDRSMN1; SMN2ALDH1A1HPGD
SCHEMBL31750885 0.72 KDM4E (0.47) KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL13685826 0.72 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884123-B2 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-02-08 US disclosed
US-7884123-B2 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-02-08 US disclosed
US-7595320-B2 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-29 US disclosed
US-7595320-B2 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-29 US disclosed
US-7595320-B2 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-29 US disclosed
EP-1858898-B1 HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE AVENTIS PHARMA SA (FR) 2009-08-26 EP disclosed
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-19 US disclosed
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-19 US disclosed
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-19 US disclosed
US-20080058402-A1 Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-03-06 US disclosed
US-20080058402-A1 Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CASP3 KDM4E 2017/4885CSNK2A2 885/4885KDR 1741/4885
US-20080058402-A1 Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof TYMS, TYMP, CYP3A43 KDM4E 3213/4885CSNK2A2 730/4885KDR 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.